EI
PETX

EAM Investors’s Aratana Therapeutics, Inc. PETX Stock Holding History

EAM Investors’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-168,075
Closed -$1.57M – 405
2016
Q3 		$1.57M Buy
+168,075
New +$1.4M 0.21% 212
2015
Q2 		– Sell
-228,672
Closed -$3.66M – 409
2015
Q1 		$3.66M Buy
228,672
+80,469
+54% +$1.43M 0.42% 60
2014
Q4 		$2.64M Buy
+148,203
New +$1.85M 0.37% 93

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EAM Investors's PETX Position: Q4 2016 in Review

EAM Investors sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2016, closing a stake of 168,075 shares — an estimated $1.57M sold.

EAM Investors first reported a position in PETX in Q4 2014 and held it in 3 quarters. The position peaked at $3.66M in Q1 2015. 107 funds tracked by Wall St. Rank hold PETX as of Q4 2016.

  • EAM Investors reported no remaining Aratana Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • EAM Investors sold 168,075 Aratana Therapeutics, Inc. shares in Q4 2016, an estimated $1.57M.
  • EAM Investors first reported a position in Aratana Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • EAM Investors's Aratana Therapeutics, Inc. position peaked at $3.66M in Q1 2015.
  • 107 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2016.

Based on EAM Investors's 13F filing for Q4 2016, filed 14 Feb 2017.